It is time to rethink the dual antiplatelet therapy indication in revascularization surgery

JOE Bono, JPR Bratti - Revista de la Federación Argentina de …, 2023 - revistafac.org.ar
Dual antiplatelet therapy (DAP) in coronary artery bypass grafting (CABG) surgery in the
context of stable ischemic heart disease is in increasing development, although ACC/AHA …

[PDF][PDF] Laura M. Willemsen, Paul WA Janssen, Chris M. Hackeng, Johannes C. Kelder, Jan GP Tijssen, Albert HM van Straten, Mohammed A. Soliman-Hamad, Vera …

EJ Daeter, U Sonker, P Klein… - … and hemostasis in …, 2022 - cris.maastrichtuniversity.nl
Background Saphenous vein graft (SVG) occlusion is reported in 6.8-26% of grafts in the
first year after coronary artery bypass grafting (CABG)(1–3). Graft occlusion is correlated …

[PDF][PDF] ЭФФЕКТИВНОСТЬ МНОЖЕСТВЕННОГО КОРОНАРНОГО ШУНТИРОВАНИЯ АРТЕРИЙ ДИАМЕТРОМ МЕНЕЕ 1, 5 ММ

ВЮ ЗАЙКОВСКИЙ - cardioweb.ru
Коронарное шунтирование (КШ) в настоящее время является одним из наиболее
частых хирургических вмешательств в Европе (от 18 до 91 на 100000 жителей)[92] …

[PDF][PDF] Курбанов Саид Курбанович

РС Акчурин - cardioweb.ru
Основной и наиболее типичной формой коронарной болезни сердца является
сегментарное поражение венечных артерий, когда в процесс атеросклероза …

[HTML][HTML] Evidence review for dual antiplatelet therapy

NGC UK - 2020 - ncbi.nlm.nih.gov
The mechanism of acute coronary syndromes (ACS) involves a break in the inner (intimal)
lining of the coronary arteries that exposes underlying atheroma to blood flow in the artery …

[PDF][PDF] The Role of Current Major Antiplatelet Agents in Cardiovascular Diseases

Z Zhou, L Huang, H Luo, X Zhu - 2020 - meddocsonline.org
Abstract Coronary Artery Disease (CAD), a primary cause of morbidity and mortality
worldwide, has arrived at a prevalence because of the quick modernization of the …

Moving from dual antiplatelet therapy to monotherapy based on P2Y12 receptor blockade—why it could be a novel paradigm?

J Nicolas, R Goel, B Claessen, R Mehran - Dual Antiplatelet Therapy for …, 2021 - Elsevier
Pivotal clinical trials conducted in the bare metal stent and first-generation drug-eluting stent
(DES) eras established the superiority of dual antiplatelet therapy (DAPT) over aspirin …

[HTML][HTML] Corresponding Author (s): Xiao Zhu & Hui Luo The Marine Biomedical Research Institute, Guangdong Medical University, Zhanjiang, China xzhu@ gdmu …

Z Zhou, L Huang, H Luo, X Zhu - meddocsonline.org
Abstract Coronary Artery Disease (CAD), a primary cause of morbidity and mortality
worldwide, has arrived at a prevalence because of the quick modernization of the …

Moving from dual antiplatelet therapy to monotherapy based on P2Y blockadedwhy 12 receptor it could be

J Nicolas, R Goel, B Claessen… - Dual Antiplatelet Therapy …, 2021 - books.google.com
Dual antiplatelet therapy (DAPT), consisting of aspirin and a P2Y12 receptor inhibitor, is
considered mandatory for all patients following percutaneous revascularization or after an …

Commentary: Better late than never!

AM Calafiore, M Di Mauro - The Journal of Thoracic and Cardiovascular …, 2019 - jtcvs.org
There is evidence that patients undergoing coronary artery bypass graft (CABG) procedure
have increased platelet activity, becoming hypercoagulable during the postoperative period …